CRISPR Therapeutics CRSP Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's retained earnings?
- CRISPR Therapeutics (CRSP) reported retained earnings of -$2.07B in Q1 2026.
- How has CRISPR Therapeutics's retained earnings changed year-over-year?
- CRISPR Therapeutics's retained earnings decreased by 37.9% year-over-year, from -$1.5B to -$2.07B.
- What is the long-term trend for CRISPR Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's retained earnings has grown at a 27.7% compound annual growth rate (CAGR), from -$573.58M to -$1.95B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.